ARF4 and neoplasm: This combination potentially reduces tumor progression by targeting centrin-specific protease 1 (SENP1) and ADP-ribosylation factor 4 (ARF4) and decreasing the production of α-smooth muscle actin and tropomyosin-1 confirmed in both laboratory and animal model studies (138).